Print page
E-mail page
Download PDF
« Previous Release | Next Release »
ST. DAVID'S, Bermuda, Aug 08, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Warner Chilcott Limited (Nasdaq: WCRX) today announced its results for the quarter ended June 30, 2008. Revenue in the quarter ended June 30, 2008 totaled $234.2 million, an increase of 3.2%, over the prior year quarter. The primary drivers of the increase in revenue were the net sales of our promoted products LOESTRIN 24 FE, FEMCON FE, TACLONEX and DORYX, which together contributed $27.0 million of revenue growth for the quarter ended June 30, 2008 compared to the prior year quarter. The growth delivered by these products was offset primarily by a significant decline in ESTROSTEP FE revenue due to generic competition.
The Company reported net income of $33.6 million ($0.13 per diluted share) in the quarter ended June 30, 2008, compared with net income of $7.9 million ($0.03 per diluted share) in the prior year quarter. Cash net income ("CNI") in the quarter ended June 30, 2008 was $84.3 million, an increase of $19.6 million, compared to $64.7 million in the prior year quarter. Included in the quarter ended June 30, 2007 was a $10.0 million expense related to the settlement of the OVCON 35 litigation. Excluding the after-tax impact of this settlement in the quarter ended June 30, 2007, adjusted cash net income of $84.3 million in the quarter ended June 30, 2008 increased $9.8 million, or 13.2%, compared to $74.5 million in the prior year quarter.
References in this release to "cash net income" or "CNI" mean the Company's net income adjusted for the after-tax effects of two non-cash items: amortization of intangible assets and amortization (or write-off) of deferred loan costs related to the Company's debt. Reconciliations from the Company's reported results in accordance with US GAAP to cash net income, adjusted cash net income and adjusted EBITDA for all periods are presented in the tables at the end of this press release.
Revenue
Revenue in the quarter ended June 30, 2008 was $234.2 million, an increase of $7.2 million, or 3.2%, over the prior year quarter. The primary drivers of the increase in revenue were the net sales of our promoted products LOESTRIN 24 FE, FEMCON FE, TACLONEX and DORYX, which together contributed $27.0 million of revenue growth for the quarter ended June 30, 2008, compared to the same quarter last year. Changes in the net sales of our products are a function of a number of factors including changes in: market demand, gross selling prices, sales-related deductions from gross sales to arrive at net sales and the levels of pipeline inventories of our products held by our customers. We use IMS estimates of filled prescriptions for our products as a proxy for market demand.
Sales of our oral contraceptive products increased $7.8 million, or 12.3%, in the quarter ended June 30, 2008, compared with the prior year quarter. LOESTRIN 24 FE generated revenue of $50.2 million in the quarter ended June 30, 2008, an increase of 44.7% compared with $34.7 million in the prior year quarter. The increase in LOESTRIN 24 FE net sales was primarily due to a 31.5% increase in filled prescriptions over the prior year quarter and, to a lesser extent, higher average selling prices. We introduced and began commercial sales of FEMCON FE in the second half of 2006, but did not initiate promotional efforts in support of the product until April 2007. The product generated revenue of $10.7 million in the quarter ended June 30, 2008 compared to $6.4 million in the prior year quarter. The increase in FEMCON FE net sales was primarily due to a 73.4% increase in filled prescriptions and higher average selling prices over the prior year quarter, offset partially by the impact of higher sales-related deductions in the quarter ended June 30, 2008. ESTROSTEP FE net sales decreased $13.7 million, or 68.3%, in the quarter ended June 30, 2008, compared to the same quarter last year. The decrease in ESTROSTEP FE net sales was primarily due to an 81.2% decline in filled prescriptions versus the prior year quarter as a result of the introduction of generic versions of ESTROSTEP FE in the fourth quarter of 2007, including our authorized generic Tilia(TM) FE. Our revenue from net sales of Tilia(TM) FE partially offset the decline in ESTROSTEP FE net sales.
Sales of our dermatology products increased $7.2 million, or 7.4%, in the quarter ended June 30, 2008, compared to the prior year quarter. Sales of DORYX increased $3.4 million, or 12.1%, in the quarter ended June 30, 2008, primarily due to higher average selling prices compared to the prior year quarter, as well as an 8.0% increase in filled prescriptions, offset in part by a contraction of pipeline inventories during the quarter ended June 30, 2008 relative to the same quarter last year. Sales of TACLONEX increased $3.8 million, or 10.9%, to $38.8 million in the quarter ended June 30, 2008, compared to $35.0 million in the prior year quarter. Sales of TACLONEX, increased primarily due to increases in filled prescriptions and higher average selling prices in the quarter ended June 30, 2008 compared to the prior year quarter. These increases were offset, in part, by a contraction of pipeline inventories during the quarter ended June 30, 2008 relative to the quarter ended June 30, 2007. Sales of DOVONEX were flat in the quarter ended June 30, 2008 compared to the prior year quarter, as higher average selling prices offset a 22.8% decline in filled prescriptions. We believe the continuing decline in filled prescriptions of DOVONEX is due primarily to customers switching to other therapies and, in part, due to the introduction of generic versions of DOVONEX solution into the market in the second quarter of 2008, including our authorized generic marketed by Hi-Tech. We expect generic competition to continue to have an adverse impact on our DOVONEX solution revenues.
Sales of our hormone therapy products were flat in the quarter ended June 30, 2008 compared to the prior year quarter. Sales of ESTRACE CREAM increased $2.2 million, or 11.3%, in the quarter ended June 30, 2008 compared to the prior year quarter, primarily due to higher average selling prices. Filled prescriptions for ESTRACE CREAM were flat in the quarter ended June 30, 2008, compared with the prior year quarter. Sales of FEMHRT decreased $0.9 million, or 5.0%, in the quarter ended June 30, 2008 compared to the prior year quarter, due to a 14.5% decrease in filled prescriptions, which was offset partially by higher average selling prices and an expansion in pipeline inventories in the quarter ended June 30, 2008.
Cost of Sales (excluding amortization of intangible assets)
Cost of sales increased $4.7 million, or 10.2%, in the quarter ended June 30, 2008, compared with the prior year quarter. Our gross profit margin, as a percentage of total revenue decreased to 78.2%, in the quarter ended June 30, 2008 from 79.6% in the prior year quarter. Our gross profit margin, as a percentage of total revenue decreased due to a number of factors, primarily the mix of products sold during the quarter and a general increase in costs relative to the prior year quarter.
Selling, General and Administrative ("SG&A") Expenses
SG&A expenses for the quarter ended June 30, 2008 were $47.1 million, a decrease of $23.1 million, or 32.9%, from $70.2 million in the prior year quarter. Advertising and promotion expenses for the quarter ended June 30, 2008 decreased $12.1 million, or 54.0%, compared with the prior year quarter, primarily due to a $10.1 million decrease in direct-to-consumer advertising, as well as an overall decrease in promotional spending. Selling and distribution expenses for the quarter ended June 30, 2008 increased $0.7 million, or 3.1%, over the prior year quarter, primarily due to normal inflationary increases during the quarter ended June 30, 2008. General, administrative and other ("G&A") expenses in the quarter ended June 30, 2008 decreased $11.7 million, or 45.8%, over the prior year quarter. The decrease in G&A is due, in part, to a reduction in legal fees of $1.2 million in the quarter ended June 30, 2008 as compared to the prior year quarter. In addition, the quarter ended June 30, 2007 included a $10.0 million expense related to the settlement of a class action lawsuit in connection with the Company's OVCON 35 litigation.
Research and Development ("R&D")
Our investment in R&D for the quarter ended June 30, 2008 was $12.5 million, an increase of $1.3 million, or 11.6%, compared with the prior year quarter. The increase in R&D activities was mainly due to costs incurred for clinical studies relating to two oral contraceptives as well as new projects which were initiated towards the end of 2007 and early 2008. We completed the enrollment of the clinical study for a new low-dose oral contraceptive in July 2007 and completed the enrollment for a second new oral contraceptive in December 2007. Our product development activities are mainly focused on improvements to our existing products, new and enhanced dosage forms and new products delivering compounds which have been previously shown to be safe and effective.
Net Interest Expense
Net interest expense for the quarter ended June 30, 2008 was $24.6 million, a decrease of $6.5 million, or 21.0%, from $31.1 million in the prior year quarter. Included in net interest expense in the quarter ended June 30, 2008 was $1.1 million relating to the write-off of deferred loan costs associated with the optional prepayment of $70.0 million of indebtedness under our senior secured credit facility, as compared to $2.6 million in the quarter ended June 30, 2007 as a result of the optional prepayment of $130.0 million of indebtedness under our senior secured credit facility. The decrease in net interest expense in the 2008 period was primarily the result of cumulative reductions in outstanding debt during 2007 which reduced the average debt balance outstanding from $1,487.8 million in the quarter ended June 30, 2007 to $1,198.2 million in the quarter ended June 30, 2008. The cumulative reduction in the average debt level is the result of optional prepayments made using cash flows from operations and cash on hand, net of investing activities.
Income taxes
Our effective tax rate for the quarter ended June 30, 2008 was 26.8%. The Company expects its annual effective tax rate for the year ended December 31, 2008 to approximate 17.5%. The effective tax rate for the quarter ended June 30, 2008 differs from the estimate of the full year 2008 due to the impact of discrete items on the current quarter's calculation.
Net Income and Cash Net Income
For the quarter ended June 30, 2008, reported net income was $33.6 million, or $0.13 per share, and CNI was $84.3 million, or $0.34 per share, based on 250.5 million diluted Class A common shares outstanding. In calculating CNI, we add back the after-tax impact of the amortization of intangible assets and the amortization and write-off of deferred financing costs. These items are tax-effected at the estimated marginal rates attributable to them. In the quarter ended June 30, 2008, the marginal tax rate associated with the amortization of intangible assets was 9.0% and the marginal tax rate for amortization and write-off of deferred financing costs was 12.2%.
Liquidity, Balance Sheet and Cash Flows
As of June 30, 2008, our cash and cash equivalents totaled $21.2 million and our total debt outstanding was $1,126.1 million. There were no borrowings outstanding under the revolving portion of our senior secured credit facility. We generated $122.8 million of cash from operating activities in the quarter ended June 30, 2008, compared with $133.6 million of cash from operating activities in the prior year quarter, a decrease of $10.8 million. The decrease in cash flows from operating activities is due to normal fluctuations in working capital.
2008 Financial Guidance Update
Based on the year to date results and current outlook for the remainder of 2008, the Company is updating its full year 2008 financial guidance. For 2008, the Company continues to anticipate revenue to be in the range of $935 to $945 million.
Total SG&A expenses are now expected to be in the range of $208 to $217 million, a decrease of $15 million from the guidance given in May 2008. This primarily reflects a decrease in estimated general and administrative expenses, mainly the expected reduction in legal fees.
Total R&D expenses are now expected to be $64 to $67 million, an increase of $7 million from the guidance given in May 2008. The revised guidance includes $12.5 million of milestone payments to third parties anticipated during the second half of 2008, offset partially by a reduction in spending on internal R&D projects.
In addition, the Company now anticipates that its income tax provision in 2008 will be in the range of 7.5% to 8.5% of earnings before taxes and book amortization ("EBTA"). The guidance includes the Company's latest estimate of pretax income by tax jurisdiction.
Based on the revised guidance, the Company continues to expect GAAP net income to be in the range of $129 to $142 million. The Company continues to expect CNI, which adds back the after tax impact of book amortization of intangible assets and the amortization and write off of deferred financing costs, to be in the range of $326 to $339 million. Using 251.0 million Class A common shares, the Company continues to anticipate CNI per share to be in the range of $1.30 to $1.35 for the full year 2008.
Investor Conference Call
The Company is hosting a conference call open to all interested parties, on Friday, August 8, 2008 beginning at 8:00 AM EDT. The number to call within the United States and Canada is (877) 545-1403. Participants outside the United States and Canada should call (719) 325-4916. A replay of the conference call will be available from two hours after the call through midnight EDT on August 22, 2008 and can be accessed by dialing (888) 203-1112 from within the United States and Canada or (719) 457-0820 from outside the United States and Canada. The replay ID number is 4102838.
The Company
Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women's healthcare and dermatology segments of the U.S. pharmaceuticals market. The Company is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. WCRX-F
Forward Looking Statements
This press release contains forward-looking statements, including statements concerning our operations, our economic performance and financial condition, and our business plans and growth strategy and product development efforts. These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," intend," "outlook," "believe" and other similar expressions are intended to identify forward- looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties.
The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness; competitive factors in the industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facility to produce our products or production or regulatory problems with either third party manufacturers upon whom we may rely for some of our products or our own manufacturing facility; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; the other risks identified in our Annual Report on Form 10-K for the year ended December 31, 2007; and other risks detailed from time-to-time in our public filings, financial statements and other investor communications.
We caution you that the foregoing list of important factors is not exclusive. In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may not occur. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be required by law.
Reconciliations to GAAP Net Income
Cash Net Income and Adjusted Cash Net Income
To supplement its condensed consolidated financial statements presented in accordance with US GAAP, the Company is providing a summary to show the computation of CNI and adjusted cash net income to add back certain non-cash and one-time or nonrecurring charges. The Company believes that the presentation of CNI and adjusted cash net income provides useful information to both management and investors concerning the approximate impact of the above items. The Company also believes that considering the effect of these items allows management and investors to better compare the Company's financial performance from period-to-period, and to better compare the Company's financial performance with that of its competitors. The presentation of this additional information is not meant to be considered in isolation of, or as a substitute for, results prepared in accordance with US GAAP.
Adjusted EBITDA
To supplement its condensed consolidated financial statements presented in accordance with US GAAP, the Company is providing a summary to show the computation of adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA") taking into account certain charges that were taken during the quarters and six months ended June 30, 2008 and 2007. The computation of adjusted EBITDA is based on the definition of EBITDA contained in the indenture governing the Company's Senior Subordinated Notes due 2015.
WARNER CHILCOTT LIMITED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands of U.S. dollars, except per share amounts)
(Unaudited)
Quarter Ended Six Months Ended
Jun-30-08 Jun-30-07 Jun-30-08 Jun-30-07
REVENUE:
Product net sales $229,636 $223,796 $453,336 $439,955
Other revenue 4,580 3,177 10,363 5,439
Total revenue 234,216 226,973 463,699 445,394
COSTS & EXPENSES:
Cost of sales (excludes
amortization) 51,012 46,296 98,782 96,893
Selling, general and
administrative 47,097 70,150 102,324 148,048
Research and development 12,546 11,238 24,726 18,670
Amortization of intangible
assets 53,137 57,554 105,750 115,107
Interest (income) (377) (1,702) (795) (3,033)
Interest expense 24,968 32,821 49,404 65,096
INCOME BEFORE TAXES 45,833 10,616 83,508 4,613
Provision for income taxes 12,265 2,719 16,282 1,218
NET INCOME $33,568 $7,897 $67,226 $3,395
Earnings per share:
Class A - Basic $0.13 $0.03 $0.27 $0.01
Class A - Diluted $0.13 $0.03 $0.27 $0.01
RECONCILIATIONS:
Net income - GAAP $33,568 $7,897 $67,226 $3,395
+ Amortization of intangible
assets, net of tax 48,358 52,607 96,264 105,214
+ Amortization of deferred loan
costs, net of tax 2,349 4,159 3,651 7,063
Cash net income $84,275 $64,663 $167,141 $115,672
Non-recurring, one-time charges
included above (net of tax):
+ Expenses related to litigation
settlements - 9,800 - 17,150
ADJUSTED CASH NET INCOME $84,275 $74,463 $167,141 $132,822
WARNER CHILCOTT LIMITED
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands of U.S. dollars)
(Unaudited)
As of As of
June 30, 2008 December 31, 2007
ASSETS
Current assets:
Cash & cash equivalents $21,210 $30,776
Accounts receivable, net 80,998 65,774
Inventories 60,279 54,031
Prepaid expenses & other current assets 59,596 65,735
Total current assets 222,083 216,316
Other assets:
Property, plant and equipment, net 59,729 57,453
Intangible assets, net 1,269,477 1,329,427
Goodwill 1,250,324 1,250,324
Other non-current assets 26,651 31,454
TOTAL ASSETS $2,828,264 $2,884,974
LIABILITIES
Current liabilities:
Accounts payable $11,019 $17,883
Accrued expenses & other current
liabilities 155,410 196,362
Current portion of long-term debt 7,552 8,284
Total current liabilities 173,981 222,529
Other liabilities:
Long-term debt, excluding current
portion 1,118,545 1,191,955
Other non-current liabilities 110,023 116,070
Total liabilities 1,402,549 1,530,554
SHAREHOLDERS' EQUITY 1,425,715 1,354,420
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY $2,828,264 $2,884,974
WARNER CHILCOTT LIMITED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW
(in thousands of U.S. dollars)
(Unaudited)
Quarter Ended Six Months Ended
June-30-08 June-30-07 June-30-08 June-30-07
CASH FLOWS FROM OPERATING
ACTIVITIES:
Net income $33,568 $7,897 $67,226 $3,395
Adjustments to reconcile net
income to net cash provided
by operating activities:
Depreciation 3,124 2,356 6,049 4,710
Amortization of intangible
assets 53,137 57,554 105,750 115,107
Amortization of debt
finance costs 2,676 4,474 4,235 7,667
Stock compensation expense 2,195 1,686 4,005 3,371
Changes in assets and liabilities:
Decrease / (increase) in
accounts receivable,
prepaid and other assets 4,303 13,754 (4,311) 3,963
Decrease / (increase) in
inventories 458 17,224 (6,248) 14,671
Increase / (decrease) in
accounts payable, accrued
& other liabilities 13,020 16,318 (812) 26,023
Increase / (decrease) in
income taxes and other, net 10,335 12,369 (55,760) 12,776
Net cash provided by
operating activities $122,816 $133,632 $120,134 $191,683
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of intangible
assets (42,900) (7,200) (45,800) (14,400)
Capital expenditures (3,068) (4,185) (10,013) (7,994)
Net cash (used in)
investing activities $(45,968) $(11,385) $(55,813) $(22,394)
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments under bank
term credit facility (72,071) (132,795) (74,142) (195,743)
Other 194 (15) 255 (71)
Net cash (used in)
financing activities $(71,877) $(132,810) $(73,887) $(195,814)
Net increase / (decrease)
in cash and cash
equivalents $4,971 $(10,563) $(9,566) $(26,525)
Cash and cash equivalents,
beginning of period 16,239 68,502 30,776 84,464
Cash and cash equivalents,
end of period $21,210 $57,939 $21,210 $57,939
WARNER CHILCOTT LIMITED
Reconciliation of Net Income to Adjusted EBITDA
(In thousands of U.S. dollars)
(Unaudited)
Quarter Ended Six Months Ended
June-30-08 June-30-07 June-30-08 June-30-07
RECONCILIATION TO ADJUSTED EBITDA:
Net income - GAAP $33,568 $7,897 $67,226 $3,395
+ Interest expense, net 24,591 31,119 48,609 62,063
+ Provision for income taxes 12,265 2,719 16,282 1,218
+ Non-cash share-based
compensation expense 2,195 1,686 4,005 3,371
+ Depreciation 3,124 2,356 6,049 4,710
+ Amortization of intangible
assets 53,137 57,554 105,750 115,107
+ Litigation settlements - 10,000 - 17,500
Adjusted EBITDA of WCL,
as defined $128,880 $113,331 $247,921 $207,364
+ Expenses of WCL and other 969 1,220 2,770 2,451
Adjusted EBITDA of Warner
Chilcott Holdings Company
III, Ltd., as defined $129,849 $114,551 $250,691 $209,815
Note: Warner Chilcott Holdings Company III, Limited and certain of its
subsidiaries are parties to our credit agreement and the indenture
governing our Senior Subordinated Notes due 2015. Warner Chilcott Limited
is not a party to these agreements. Certain expenses included in Warner
Chilcott Limited's consolidated operating results are not deducted in
arriving at Adjusted EBITDA for Warner Chilcott Holdings Company III, Ltd
and its subsidiaries.
WARNER CHILCOTT LIMITED
REVENUE BY PRODUCT
(In millions of U.S. dollars)
(Unaudited)
Quarter Ended Six Months Ended
June-30-08 June-30-07 June-30-08 June-30-07
Oral Contraception ("OC")
LOESTRIN 24 FE $50.2 $34.7 $97.1 $69.1
FEMCON FE 10.7 6.4 21.5 11.5
ESTROSTEP FE * 6.4 20.1 11.0 42.1
OVCON * 4.0 2.3 6.8 6.9
Total OC 71.3 63.5 136.4 129.6
Hormone therapy ("HT")
ESTRACE Cream 21.2 19.0 40.4 34.7
FEMHRT 16.4 17.3 32.4 30.5
FEMRING 3.4 3.8 6.9 7.3
Other HT 2.5 3.4 5.4 7.3
Total HT 43.5 43.5 85.1 79.8
Dermatology
DORYX 31.7 28.3 66.8 55.0
TACLONEX 38.8 35.0 75.8 64.2
DOVONEX * 33.5 33.5 66.6 75.4
Total Dermatology 104.0 96.8 209.2 194.6
PMDD
SARAFEM 7.8 9.1 12.2 18.4
Other product sales
Other (1.1) 1.1 (0.9) 2.1
Contract manufacturing 4.1 9.8 11.3 15.5
Total product net sales 229.6 223.8 453.3 440.0
Other revenue
Other non-product revenue 4.6 3.2 10.4 5.4
Total revenue $234.2 $227.0 $463.7 $445.4
* Includes revenue from related authorized generic product sales from
the date of their respective launch.
WARNER CHILCOTT LIMITED
SUMMARY OF SG&A EXPENSES
(In millions of U.S. dollars)
(Unaudited)
Quarter Ended
June-30-08 June-30-07
Advertising & promotion $10.3 $22.4
Selling & distribution 23.0 22.3
General, administrative & other 13.8 25.5
Total SG&A $47.1 $70.2
Six Months Ended
June-30-08 June-30-07
Advertising & promotion $27.5 $53.7
Selling & distribution 46.6 44.0
General, administrative & other 28.2 50.3
Total SG&A $102.3 $148.0
Warner Chilcott Limited
2008 Full Year Financial Guidance
(U.S. dollars in millions, except per share)
Guidance Revised Guidance
May 2008 August 2008
Total Revenue (1) $935 to $945 $935 to $945
Gross margin as a % of revenue 80% to 81% 80% to 81%
SG&A Expenses:
Selling & Distribution $93 to $96 $93 to $96
A&P $57 to $60 $54 to $57
G&A $73 to $76 $61 to $64
Total SG&A Expenses (2) $223 to $232 $208 to $217
Total R&D (3) $57 to $60 $64 to $67
Total income tax provision (4) 5.5% to 6.5% of EBTA 7.5% to 8.5% of EBTA
GAAP Net Income $129 to $142 $129 to $142
Cash Net Income ("CNI") (5) $326 to $339 $326 to $339
CNI per share (5) (6) $1.30 to $1.35 $1.30 to $1.35
(1) Revised guidance includes the expected impact of generic competition
introduced in the second quarter of 2008 for SARAFEM and DOVONEX
solution. Guidance does not account for the impact of any future new
licensing agreements.
(2) Total SG&A expense does not include any amount that may be payable in
connection with the potential settlement of our outstanding legal
actions.
(3) The revised guidance includes $12.5 million related to third party R&D
milestone payments.
(4) The total 2008 tax provision is estimated as a % of earnings before
taxes and book amortization ("EBTA").
(5) A reconciliation of 2008 GAAP net income to CNI adds back the expected
after tax impact of the amortization of intangibles ($189M) and the
expected after tax impact of deferred financing fees ($8M).
(6) CNI per share is based on 251.0 million fully diluted Class A shares.
SOURCE Warner Chilcott Limited
http://www.warnerchilcott.com
Copyright (C) 2008 PR Newswire. All rights reserved
News Provided by COMTEX